Table 1.
Baseline characteristics of the 81 subjects who completed the CFRDT trial
| CFRD FH− |
IGT |
|||||||
|---|---|---|---|---|---|---|---|---|
| Total cohort | Insulin | Repaglinide | Placebo | Total cohort | Insulin | Repaglinide | Placebo | |
| n | 61 | 23 | 22 | 16 | 20 | 7 | 4 | 9 |
| n (% female) | 31 (51)* | 12 (52) | 11 (50) | 8 (50) | 5 (25) | 3 (43) | 0 (0) | 2 (22) |
| Age (years) | 28 ± 9 | 29 ± 2 | 26 ± 2 | 28 ± 3 | 28 ± 7 | 27 ± 2 | 29 ± 5 | 28 ± 2 |
| BMI (kg/m2) | 21.3 ± 2.9 | 20.6 ± 0.6 | 21.3 ± 0.7 | 22.2 ± 0.6 | 22.0 ± 2.7 | 20.7 ± 0.7 | 22.9 ± 1.7 | 22.5 ± 0.9 |
| % Fat-free mass | 79 ± 9 | 79 ± 2 | 80 ± 2 | 77 ± 2 | 80 ± 8 | 81 ± 3 | 79 ± 5 | 80 ± 3 |
| FVC (% predicted) | 90 ± 22 | 87 ± 4 | 90 ± 6 | 94 ± 4 | 88 ± 17 | 79 ± 7 | 82 ± 10 | 98 ± 4 |
| FEV1 (% predicted) | 70 ± 25 | 63 ± 5 | 71 ± 6 | 78 ± 5 | 69 ± 21 | 61 ± 7 | 61 ± 13 | 78 ± 6 |
| NIH score | 83 ± 13 | 80 ± 3 | 84 ± 3 | 88 ± 3 | 82 ± 14 | 79 ± 6 | 74 ± 9 | 89 ± 2 |
| A1C (%) | 6.1 ± 0.6* | 6.2 ± (0.1) | 6.2 ± 0.1 | 6.0 ± 0.1 | 5.5 ± 0.4 | 5.5 ± 0.3 | 5.6 ± 0.1 | 5.5 ± 0.1 |
Data for the CFRD FH− and IGT total cohorts are means ± SD; data by treatment group as means ± SEM. There were no significant differences across treatment groups for CFRD FH− or IGT.
*Total cohort CFRD FH− vs. IGT, P < 0.05.